Can­cer drug to treat dwarfism? Aban­doned No­var­tis as­set snagged by Bridge­Bio’s QED Ther­a­peu­tics

Bridge­Bio is snatch­ing a re­cent­ly-aban­doned can­cer pro­gram off No­var­tis’ shelves, hand­ing the as­set to a spin­out com­pa­ny with un­usu­al plans for the drug.

The new­ly-li­censed prod­uct — called in­fi­gra­tinib or BGJ398 — was in Phase II tri­als at No­var­tis for pa­tients with bile duct can­cer with FGFR fu­sions. Al­though the drug showed mean­ing­ful clin­i­cal ac­tiv­i­ty ear­ly in the tri­al, No­var­tis de­cid­ed to dump the drug last year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.